Celularity Inc

Celularity Inc., listed under ticker GXGX, is a clinical-stage cellular medicine company that completed its de-SPAC business combination with GX Acquisition Corp. II in 2021, following that blank-check vehicle's IPO in 2020 under the sponsorship of GX Sponsor II LLC. Focused on developing placenta-derived allogeneic cell therapies across oncology and infectious disease indications, Celularity operates in the biotechnology sector and remains a public reporting company subject to SEC disclosure obligations. The company filed an 8-K on January 17, 2024, bearing accession number 0000950170-24-005029, as part of its ongoing regulatory reporting. Sign up at SpacDesk for full filing histories, sponsor profiles, and deal analytics on GXGX and hundreds of additional SPAC transactions.